Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBLI
CUSIPN/A
Phone716-849-6810
Debt
Debt-to-Equity RatioN/A
Current Ratio3.86
Quick Ratio3.86
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.95 million
Price / Sales14.83
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book3.88
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-9,700,000.00
Net Margins-578.89%
Return on Equity-115.60%
Return on Assets-90.24%
Miscellaneous
Employees19
Outstanding Shares11,300,000
Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions
What is Cleveland BioLabs' stock symbol?
Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."
How were Cleveland BioLabs' earnings last quarter?
Cleveland BioLabs, Inc. (NASDAQ:CBLI) released its quarterly earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.11) earnings per share for the quarter. The biotechnology company had revenue of $0.23 million for the quarter. Cleveland BioLabs had a negative net margin of 578.89% and a negative return on equity of 115.60%. View Cleveland BioLabs' Earnings History.
Who are some of Cleveland BioLabs' key competitors?
Some companies that are related to Cleveland BioLabs include HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International, Inc common stock (DYAI), Vitality Biopharma (VBIO), BIOQUAL (BIOQ), Protalex (PRTX), Bioanalytical Systems (BASI), US Stem Cell (USRM), Tenax Therapeutics (TENX), Geovax Labs (GOVX), ALGAE TEC Ltd/S (ALGXY) and Redpoint Bio (RPBC).
Who are Cleveland BioLabs' key executives?
Cleveland BioLabs' management team includes the folowing people:
- Dr. Yakov N. Kogan Ph.D., MBA, Chief Exec. Officer and Interim Principal Financial Officer (Age 45)
- Dr. Langdon L. Miller, Pres & Chief Medical Officer (Age 64)
- Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 62)
- Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory Affairs
- Dr. Andrei Purmal Ph.D., VP of Chemistry
Has Cleveland BioLabs been receiving favorable news coverage?
News headlines about CBLI stock have been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cleveland BioLabs earned a news sentiment score of 0.10 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 47.79 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Cleveland BioLabs?
Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cleveland BioLabs' stock price today?
One share of CBLI stock can currently be purchased for approximately $2.56.
How big of a company is Cleveland BioLabs?
Cleveland BioLabs has a market capitalization of $28.92 million and generates $1.95 million in revenue each year. Cleveland BioLabs employs 19 workers across the globe.
How can I contact Cleveland BioLabs?
Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]
MarketBeat Community Rating for Cleveland BioLabs (CBLI)
MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe CBLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
